Weekly oral vitamin K prophylaxis in Denmark.
OBJECTIVE
To evaluate oral vitamin K prophylaxis at birth by giving 2 mg phytomenadione, followed by weekly oral vitamin K prophylaxis; 1 mg was administered by the parents until 3 mo of age.


METHODS
A total of 507850 live babies were born in Denmark during the study period, November 1992 to June 2000. Of these infants, 78% and 22% received oral and intra-muscular prophylaxis, respectively; i.e. about 396000 neonates received oral prophylaxis at birth. Weekly oral prophylaxis was recommended for all infants as long as they were mainly breastfed. A survey of possible cases of vitamin K deficiency bleeding (VKDB) was carried out by repeated questionnaires to all Danish paediatric departments and by checking the National Patient Register.


RESULTS
No cases of VKDB were revealed, i.e. the incidence was 0-0.9:100000 (95% CI). The questionnaires were used to evaluate compliance with the regimen. Parents of 274 infants participated. A dose of vitamin K was regarded as having been given if the infant received a drop of vitamin K or was mostly formula-fed that week, and the prophylaxis was regarded as completed if the infant had received at least 9 doses. Compliance was good, with 94% of the infants completing the course of prophylaxis.


CONCLUSIONS
Weekly oral vitamin K supplementation during the first 3 mo of life was an efficient prophylaxis against VKBD. Parental compliance with the regimen was good.
Hansen
K N
KN
Department of Paediatrics, Viborg-Kjellerup Hospital, Denmark. vsb24knh@vibamt.dk
Minousis
M
M
Ebbesen
F
F
D000933:Antifibrinolytic Agents / Q000627:therapeutic use*; D001942:Breast Feeding; D002662:Child Health Services / Q000458:organization & administration; D003718:Denmark / Q000453:epidemiology; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005527:Food, Fortified; D006293:Health Promotion; D006801:Humans; D015994:Incidence; D007229:Infant Welfare; D007231:Infant, Newborn; D010349:Patient Compliance / Q000706:statistics & numerical data; D011314:Preventive Health Services / Q000458:organization & administration; D011795:Surveys and Questionnaires; D014812:Vitamin K / Q000008:administration & dosage / Q000627:therapeutic use*; D010837:Vitamin K 1 / Q000008:administration & dosage / Q000627:therapeutic use*; D014813:Vitamin K Deficiency / Q000453:epidemiology / Q000517:prevention & control*; D006475:Vitamin K Deficiency Bleeding / Q000453:epidemiology / Q000209:etiology* / Q000517:prevention & control*
D000933:Antifibrinolytic Agents; D014812:Vitamin K; D010837:Vitamin K 1